Aprea Therapeutics can begin testing of its key asset, eprenetapopt, after a series of Clinical pauses in August 2021. The biotech company intends to test…
Aprea Therapeutics can begin testing of its key asset, eprenetapopt, after a series of Clinical pauses in August 2021. The biotech company intends to test…